NCT06595563
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06595563
Title HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (ZEPHIR-02)
Acronym ZEPHIR-02
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jules Bordet Institute
Indications
Therapies
Age Groups: senior | adult
Covered Countries NLD | BEL

Facility Status City State Zip Country Details
Institut Jules Bordet Anderlecht Brussels Capital 1070 Belgium Details
CHU Charleroi - Marie Curie Charleroi 6042 Belgium Details
UZ Gent Ghent 9000 Belgium Details
UZ Leuven Leuven 3000 Belgium Details
CHU Liège Liège 4000 Belgium Details
AZ Delta Roeselare 8800 Belgium Details
VUMC Amsterdam Amsterdam 1081 Netherlands Details
UMC Groeningen Groningen 9713 Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field